FDA approves new oral drug to treat multiple sclerosis

The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm

Source: Food and Drug Administration - March 26, 2019 Category: American Health Source Type: news

More News: American Health | Food and Drug Administration (FDA) | Multiple Sclerosis